NOTICE

As we all are aware that India is passing through Novel Coronavirus Disease (COVID-19) pandemic and in order to protect the country and each of its citizens, the Hon'ble Prime Minister of India announced nationwide lockdown on 24th March, 2020 which is now gradually being relaxed to start normal operations in all sectors. Being an autonomous Institute under the Ministry of Health & Family Welfare, Government of India, Indian Pharmacopoeia Commission (IPC) is actively engaged in providing important healthcare related services to the country. In order to better serve the nation during this health emergency situation due to COVID-19, IPC continues to operate and offering its services to the stakeholders.

IPC has received representations from various stakeholders that due to the nationwide lockdown draft monograph verification at their sites is currently not possible and sourcing/testing of the drug substances and drug products is delayed owing to difficulty in procuring key consumables, reference standards, impurities and, therefore, requested for extension of publication of IP Addendum 2021 for a period of 6 months so that they can review all impacted materials/products and confirm the compliance to provide comments on draft monographs published on IPC website.

Accordingly, considering the inability of the stakeholders' to verify the draft monographs of the IP Addendum 2021 due to current COVID-19 pandemic, IPC has accepted and approved the extension of publication of IP Addendum 2021 by six months.

(Dr. Jai Prakash) 09/06/2020
Secretary-cum-Scientific Director (I/c)

To,
All the Stakeholders of IPC

Copy for Information to:
1. The PPS to Secretary (H&FW), MoH&FW, Govt. of India, Nirman Bhawan, New Delhi.
2. The PS to Joint Secretary (R), MoH&FW, Govt. of India, Nirman Bhawan, New Delhi.